Gynecologic Cancers

The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James) gynecologic research team works tirelessly to achieve their mission: to develop innovative, curative strategies so that no woman ever dies from a gynecologic cancer. Achieving this requires the team to create and conduct impactful, groundbreaking research that leads to advanced surgical treatment and training, and even more refined clinical procedures and therapies for women diagnosed with gynecologic cancers.

Working collaboratively, the OSUCCC – James gynecologic research team reaches across many disciplines – surgical, medical, gynecologic and radiation oncologists, as well as geneticists, pharmacologists and more – to share knowledge, expertise and world-class skills that move research and discoveries from the bench to the bedside.

At any given time, numerous advanced gynecologic research projects are in progress, and they are all designed and dedicated to discovering, developing and delivering research outcomes leading to the most advanced treatments, refined clinical procedures and highly-targeted precision therapies for each woman with gynecologic cancer.

Through integrative scientific research, case-based study and interdisciplinary collaboration within the lab and the clinic, the nationally and internationally recognized OSUCCC – James gynecologic cancer research experts evaluate current approaches while brainstorming emerging methodologies. In fact, these discussions are often continued from surgery into the lab where new techniques are measured, tested, refined and ultimately returned to the operating suites where groundbreaking gynecologic procedures are used to improve outcomes for women with gynecologic cancer.

Clinical Trials

The OSUCCC – James has hundreds of open clinical trials at any given time, supporting groundbreaking research made available to clinical trial patients right here in Columbus, Ohio.

Our gynecologic cancer clinical trials provide a full spectrum of opportunities for patients regardless of cancer type. From ovarian, endometrial and cervical cancers to other more rare types of tumors, trials range from national, multi-institutional trials that are looking for new standards of care to early clinical trials in which a patient may be one of only a few in the world receiving a certain therapy. In fact, the OSUCCC – James patients have access to more of this nation’s leading-edge, targeted treatments and drugs than anywhere else in the area.

Additionally, patients at the OSUCCC – James have the opportunity to enroll in maintenance trials or trials in addition to their normal treatment. 

A few of the many burgeoning scientific opportunities that this renowned research team is currently investigating include:

  • Immunotherapy – Treatment that helps your immune system fight cancer.
  • Targeted therapy – Treatment that targets the changes in cancer cells that help them grow, divide and spread.
  • Antibody-drug conjugate (ADC) – Highly targeted treatment designed to eliminate cancer cells and spare healthy cells.
  • Anti-vascular medicine – Using medications that block cancer cells’ ability to form new blood supply.
  • Tumor infiltrating lymphocyte (TIL) therapy – Specialized immune cells called lymphocytes or T cells are taken from a patient's tumor and infused back into the patient to attack the tumor.

Clinical Research Accomplishments, Scientific Presentations and Publications

The nationally and internationally recognized OSUCCC – James gynecologic research experts often present their findings and accomplishments to medical experts from around the world through presentations, publications and numerous national and international meetings and conferences that they attend throughout each year. 

Their most recent publications include:

Adjuvant Chemotherapy Plus Radiation for Locally Advanced Endometrial Cancer. Published in The New England Journal of Medicine.

  PI: David O'Malley, MD

Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High Intermediate and High-Risk Early Stage Endometrial CancerJournal of Clinical Oncology.

  PI: Ritu Salani, MD

Trebananib or Placebo Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Ovarian Cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): A Randomised, Double-Blind, Phase 3 Trial. Published in Lancet Oncology.

  PI: David O'Malley, MD

Adjuvant Gemcitabine Plus Docetaxel Followed by Doxorubicin Versus Observation for High-Grade Uterine Leiomyosarcoma: A Phase III NRG Oncology/Gynecologic Oncology Group Study. Published in Journal of Clinical Oncology.

  PI: David O'Malley, MD 

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu. Published in Journal of Clinical Oncology.

  PIs: David O'Malley, MD; Floortje Backes, MD

A Phase II Study of Frontline Paclitaxel/Carboplatin/Bevacizumab, Paclitaxel/Carboplatin/Temsirolimus or Ixabepilone/Carboplatin/Bevacizumab in advanced/recurrent endometrial cancer. Published in Gynecologic Oncology.

  PI: David O'Malley, MD

Who We Are

The OSUCCC – James gynecologic cancer research team of experts spans a broad range of disciplines – from gynecologic oncologists, surgical oncologists and radiation oncologists to molecular and biological pathologists, research scientists and more – each specializing in specific areas of gynecologic cancer research.

It’s that sub-specialization and singular focus that enables this team to discover, develop and deliver research outcomes that lead to the most advanced surgical treatments, refined clinical procedures and highly-targeted precision therapies for each patient, which can mean improved outcomes, faster responses, fewer side effects and more hope for gynecologic cancer patients everywhere.

Gynecologic Oncology:

Medical Oncology:

Radiation Oncology:

Search for Clinical Trials

Please enter a keyword (i.e. Name, Research Interest) or choose a Research Program

OR

Please enter a keyword (i.e. Name, Cancer Type) or choose a Principle Investigator

OR

Find a Scientific Publication